In the overall cohort, the incidence of treatment‐emergent serious adverse events [RR: 0.88 (0.84–0.91); P < 0.001; I2 = 0%] and risk of acute kidney injury [RR: 0.63 (0.45–0.87); P = 0.006; I2 = 14%] was significantly lower in the SGLT2 inhibitor arm. The gene discussed is SLC5A2; the disease is acute kidney injury.